The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
Autor: | Louis DN; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Perry A; Department of Pathology, University of California San Francisco, San Francisco, California, USA., Wesseling P; Department of Pathology, Amsterdam University Medical Centers/VUmc, Amsterdam, the Netherlands.; Laboratory for Childhood Cancer Pathology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Brat DJ; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Cree IA; International Agency for Research on Cancer, World Health Organization, Lyon, France., Figarella-Branger D; Service d'Anatomie Pathologique et de Neuropathologie, APHM, CNRS, Institut de Neurophysiopathologie, Hôpital de la Timone, Aix-Marseille University, Marseille, France., Hawkins C; Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada., Ng HK; Department of Anatomical and Cellular Pathology, Chinese University of Hong Kong, Hong Kong, China., Pfister SM; Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Division of Pediatric Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), and Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany., Reifenberger G; Institute of Neuropathology, University Hospital Düsseldorf and Medical Faculty, Heinrich Heine University Düsseldorf, and German Cancer Consortium (DKTK) Partner Site Essen/Düsseldorf, Düsseldorf, Germany., Soffietti R; Department of Neurology and Neuro-Oncology, University of Turin Medical School, Turin, Italy., von Deimling A; Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University, Heidelberg, Germany.; Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), and German Cancer Consortium (DKTK), Heidelberg, Germany., Ellison DW; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Neuro-oncology [Neuro Oncol] 2021 Aug 02; Vol. 23 (8), pp. 1231-1251. |
DOI: | 10.1093/neuonc/noab106 |
Abstrakt: | The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors. Building on the 2016 updated fourth edition and the work of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, the 2021 fifth edition introduces major changes that advance the role of molecular diagnostics in CNS tumor classification. At the same time, it remains wedded to other established approaches to tumor diagnosis such as histology and immunohistochemistry. In doing so, the fifth edition establishes some different approaches to both CNS tumor nomenclature and grading and it emphasizes the importance of integrated diagnoses and layered reports. New tumor types and subtypes are introduced, some based on novel diagnostic technologies such as DNA methylome profiling. The present review summarizes the major general changes in the 2021 fifth edition classification and the specific changes in each taxonomic category. It is hoped that this summary provides an overview to facilitate more in-depth exploration of the entire fifth edition of the WHO Classification of Tumors of the Central Nervous System. (© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
Databáze: | MEDLINE |
Externí odkaz: |